A third of all schizophrenia cases go undiagnosed
Only around two in three individuals with schizophrenia are diagnosed by a physician, likely due to misdiagnosis of the condition.
Comment
Merck expands haematology portfolio with acquisition of Imago for $1.35bn
Positive data for Luye Pharma’s LY03010 in schizophrenia, but faces a crowded marketop
DLBCL: a rapidly evolving treatment landscape with a crowded pipeline
Arcutis boasts positive data for topical Phase III candidate Roflumilast
Roche therapeutic gantenerumab fails trial expectations for Alzheimer’s Disease
Florida suffers Vibrio vulnificus outbreak in wake of Hurricane Ian
Roche’s gantenerumab failure boosts prospects for Eisai and Biogen’s lecanemab
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
